Figure 1From: The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 75% debulk results in delayed residual tumor outgrowth. BALB/c mice bearing AB1-HA tumors underwent surgical debulking of different percentages on day 18 post-tumour inoculation (dotted line). A. Survival and B. Residual tumour outgrowth were monitored. Surviving mice shown in brackets. ***p < 0.001 compared to untreated; log-rank test.Back to article page